title: Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?
abstract: Treatment of hepatitis C virus (HCV) with newer directly acting antivirals (DAAs) and lead to sustained viral response (SVR) in majority of patients and SVR has been documented to be associated with reversal of liver cirrhosis. The improved SVR rates and safety profiles of DAAs have led to the treatment of patients with decompensated cirrhosis awaiting liver transplantation (LT). Several clinical trials of DAAs in decompensated HCV patients have recently demonstrated SVR rates above 80%, which have been associated with significant improvements, in the Child-Pugh-Turcotte scores/or model for end-stage liver disease scores in a proportion of patients. Moreover, it has been shown that HCV RNA becomes negative after 2-4 weeks of treatment, and those who are transplanted after becoming HCV RNA negative will be have very low the risk of HCV recurrence after transplantation. Some of the patients may have reached the "point of no return" and may proceed to worsening of decomposition over time. To avoid the risk of worsening, there is an additional option of treating these patients after LT should they develop recurrent HCV infection. Currently there are no guidelines as to select patients who would benefit from treatment prior to LT as opposed to those who will be better off being treated after the transplant surgery. The article discusses a possible approach for such selection.
authors.affiliation: Indraprastha Apollo Hospital, Sarita Vihar, New Delhi, India.
authors.forename: Anil C
authors.initials: AC
authors.lastname: Anand
keywords: CSA, cyclosporine A; CTP, Child–Turcotte–Pugh staging; DAA, directly acting antivirals; DCV, daclatasvir; DDLT, deceased donor liver transplant; DSB, dasabuvir; EBV, elbasvir; FCH, fibrosing cholestatic hepatitis; GRZ, grazoprevir; GT, genotype; HCV, hepatitis C virus; IU, international units; LDLT, living donor liver transplant; LDV, ledipasvir; LT, liver transplantation; MELD, model for end-stage liver disease RNA; OMB, ombitasvir; PTV, paritaprevir; Peg-IFN, pegylated interferon alfa; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; SVR, sustained virological response, (SVR 12 signifies SVR at 12 weeks); TAC, tacrolimus; VLP, velpatasvir; decompensated cirrhosis; directly acting antivirals; hepatitis C virus infection; liver transplantation; rt, ritonavir; sustained virological response